Archive | Hot Mandates RSS feed for this section

Hot Investor Mandate 1: Healthcare & Real Estate Fund Makes Seed-Series B Biotech & Medtech Investments

23 Feb

A holding company with offices in China and the USA aims to serve human healthcare and technological development through high-tech investment and real estate investment. Through its investment arm the firm makes venture investments in healthcare. Typical allocations range from US$1-10 million in companies from Seed to Series B stages. The firm is open to leading or following in a round. The firm is looking for opportunities from US and Canada that have a China angle.

Within healthcare, the firm considers biopharmaceuticals, medical devices, diagnostics, and AR/VR/AI innovations in healthcare. The firm is focused on diseases with large market potential including oncology, infectious disease, diabetes, CNS, and cardiovascular diseases. The firm is opportunistic in terms of stage of development and typically participates in Seed to Series B rounds.

The firm is seeking innovative products and can aid with management, operations, and registration. Leveraging its resources in China, the firm can facilitate distribution in the China market. However, distribution rights are not a requirement for investment.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

Hot Investor Mandate 2: China VC Raises New Fund For US Life Science Deals

23 Feb

A venture capital firm based in China has over $2 billion in total managed assets in the areas of healthcare, technology and internet, and clean tech.  The firm invests from both a USD fund and an RMB fund, and is raising a new US fund in 2017.  The firm has invested in more than 50 healthcare companies, that span most sectors of life sciences from pharmaceuticals and medical devices to healthcare IT, diagnostics and select healthcare services. The firm intends to lead, co-lead, or co-invest in US-based private companies with equity investments ranging from $3 to $12 million.

The firm is open to many sectors in the life science space – biotech therapeutics, medical devices, diagnostics, and healthcare IT. The firm is most interested in breakthrough products and technologies that address a large unmet need. The firm seeks investments in 510K devices and we will invest in devices in the PMA pathway depending on stage, preferably clinical or later. In therapeutics, the firm is modality-agnostic, but generally seeking opportunities that are past the pre-clinical stage. The firm is also interested in enabling technologies for drug discovery and development, and other healthcare-related technologies in the “digital-health” space.

The firm is seeking to invest in companies with novel ideas and technology and experienced and passionate management. Given the firm’s slogan of “inspiring people with the wisdom to succeed with diligence”, The firm’s team is “hands-on” and typically assumes a board seat after an investment.  Investments in US companies are expected to have upside opportunities in China, and can leverage our China network and expertise.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

Hot Investor Mandate 3: Advanced Materials Corporation Invests in Drug Discovery Tech, Precision & Cell Based Medicine, IVDs and Medtech

23 Feb

A chemical and polymer manufacturer is vigorously looking to expand its business into life sciences and seeking for inorganic growth vehicles through strategic investments and acquisitions that reinforce the company’s core competencies.

The company is interested in CDMOs for the biologics field and CRO to support new drug discovery process of pharmaceutical industry.  In addition to this, the firm is looking for disruptive technologies in the fields of precision medicine, stem cell biology & cell-based medicine, Microbiome, designed medical devices and In Vitro Diagnostics.

As for CDMO, startups which have unique value proposition for the pharmaceutical industry are of interest. Regarding CROs, the firm is interested in companies based in Europe or North America with positive operating income. For other technologies, the firm would like to contact startups with at least proof of concept and strong IP. The firm is interested in co-development of these technologies, co-distribution of the product offerings and sharing of profit based on the contribution from each player.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

Hot Investor Mandate 4: China-based Pharma Seeks Early Stage Investments in Drugs, Nutraceuticals and Digital Health

23 Feb

A publicly traded pharma corporation based in China is actively pursuing strategic partnerships with other pharmaceutical companies, natural product producers, universities, hospitals and researchers and developers. The firm considers a board range of strategies including investment, joint venture, acquisition, licensing, and development funding. The firm is looking for opportunities in North America and Europe.

The firm is looking for strategic partnerships in prescription drugs, nutraceuticals, and digital health. Other sectors of interest include healthcare services, children’s health education, and senior care. The firm is open to products at all development stages. Within biopharmaceuticals, the firm takes an opportunistic approach to small molecules, biologics, and other modalities. Within digital health, the firm is looking for products that are complimentary to its pipeline.

The firm is looking to build collaborative partnerships with experienced teams in key strategic sectors. The firm can provide US regulatory expertise, global operation, and distribution channels and clinical trial sites across China.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

Hot Investor Mandate 1: Medical Corporation Seeks Early Stage Device Opportunities in Hematology, Liver Diseases and Cardiovascular

16 Feb

A China-based publicly listed enterprise specialized in blood purification is seeking to collaborate with early stage businesses with advanced technologies that are a strategic fit for its product pipeline. Equity investment size can be flexible but typically ranges from US$0.5-5 million. The firm can also consider collaborative research, licensing, and merger and acquisition. The firm is looking for new opportunities globally with a focus on the US.

The firm is interested in medical devices in the hematology, liver diseases, and cardiovascular diseases fields. The firm prefers post-prototype products with preclinical and clinical validation. Products should have a strategic angle with the firm’s pipeline of products.

The firm is looking for experienced management teams with sector expertise. The firm is interested in distribution rights in China.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

Hot Investor Mandate 2: Canada Fund Invests in Software-enabled Healthtech and Wearable Devices

16 Feb

A Canada-based venture capital firm makes investments with an average size of $5 million with reserves left for follow-on rounds. The firm seeks to make 4-5 new investments per year, and typically co-invests in seed, venture and series A investments at $50,000 – $1M per company. The firm has partnerships with medical software/device, fintech and ICT funds in which the firm will pass on deal flow. The firm has particular preference to companies located in North America, though is open to Australia and Western Europe depending on the opportunity. The firm does not request distribution rights for international investments.

The firm is interested in early-stage wearable technology and software-enabled technology, particularly ones that can improve hospital operations. The firm does not have a preference for any specific indication areas. The firm does not have revenue requirements for wearable technology and is not particularly interested in products that require regulatory pathways. The firm is interested in companies that are in the development or clinical-stage but will only invest in healthcare IT companies if it is already established with positive cash flow. Outside of software and wearable technology, the firm will look at medical devices to evaluate and connect to partnered funds.

The firm values sweat equity but the firm will not make any investments into a company unless the founding team has invested their own funds into the company’s success. The firm takes a board seat when making any new investments and looks for strong, experienced management teams. The first question the firm will ask any new opportunity is whether or not they have experience in marketing, sales, startups, or the industry they are entering. The firm can provide strategic management if necessary.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

Hot Investor Mandate 3: US VC Partners with China-based Investors to Back Life Science Companies

16 Feb

A venture capital company based in Texas makes equity investments into early stage companies generally in Angel and Seed rounds. For early stage opportunities, the firm typically invests up to $.5 million dollars but is able to invest more or less depending on the opportunity. Additionally the firm partners with a large number of investors in China who are interested in later stage opportunities where they can invest $15M-$20M. The firm is looking for companies located in the United States and generally makes 2-3 new investments per year.

The firm is looking for companies in sectors of Healthcare IT, Medical Devices, Telemedicine, Mobile Health and Bioinformatics. The firm looks for companies that have at least a prototype of their product and has made investment into several companies that have pre-market approval. The firm is agnostic in terms of subsector and indication and is very open to review any companies in their sectors of interest. More recently the firm has also gained interest into companies that are interested in accessing China market for business and investment opportunities.

The firm is looking for companies with experienced management teams and generally looks to take a board seat following investment. The firm is also open to syndication with other investors in certain cases.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com